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 INTRODUCTION 
 
Lameness investigation in the horse consists of different parts. The first part is anamnesis followed 
by static and dynamic examination that sometimes includes ridden assessment. 
In certain conditions, characteristic gait abnormalities allow immediate and straightforward 
recognition and localization of the problem. Sweeny, fibrotic myopathy, upward fixation of the 
patella, stringhalt, shivers, and radial nerve paresis may be some examples. However, similar gait 
deficits are due to a variety of lameness problems, complicating recognition and localization. A 
fundamental concept in lameness diagnosis is the application of diagnostic painful techniques to 
localize the source of pain causing lameness. The sequence of properly determining the lame leg 
(recognition) and then abolishing the clinical sign of lameness by use of diagnostic analgesia 
(localization), only to have lameness return when the local anaesthetic effects disappear, is essential 
for accurate diagnosis. In essence, diagnostic analgesia establishes clinical relevance, a most 
important concept to the lameness diagnostician. With experience and under certain circumstances, 
this step in lameness diagnosis can be omitted. The degree of lameness, certain gait characteristics, 
and palpation findings allow the clinician to strongly suspect a diagnosis. The next step may be 
diagnostic imaging examination (Ross 2011). However, because distinctive or peculiar signs are 
rare, science and proficiency in diagnostic analgesic techniques is mandatory for the lameness 
diagnostician.  
However, in some cases, it is not possible to safely perform diagnostic analgesia due to the horse 
demeanor (Buchner 1999). Therefore in these cases pharmacological restrain of the horse is the 
only option available in order to safely and precisely perform the procedure (Barr 1997). Moreover 
all the different drugs used to provide an adequate degree of sedation may also providing a dose-
dependent degree of ataxia (Alitalo 1986; Ricketts 1986), which can subsequently influence the 
final lameness assessment (Barr 1997).  
Different authors have suggested a solution to overtake this problem. In a previous study Dyson and 
Kidd (1993) suggested that the use of xylazine should be considered in order to safely perform 
navicular bursa block. In the same study it was proven that there was no difference between horses 
that received xylazine prior performing the block and those who did not. Another study   looking 
for the influence of a bolus of detomidine (10µg/kg) administered to horses (17) undergoing 
lameness investigation, showed that there was no change in the lameness scores. However, a 6% of 
increase in the amplitude of the stride was noticed as well as a 3% increase of the time of the stance 
phase. Even though the degree of lameness was not changed these changes can affect the naked eye 
of the clinician and lead to a wrong clinical judgment particularly in cases of mild alteration of the 
gait.  
The alpha-2 agonists are the family of drugs more frequently used in equine practice in order to 
provide an adequate degree of sedation. These molecules possess many of the qualities required for 
an ideal preanesthetic drug, including predictability, anxiolysis, marked sedation, stupor, and 
indifference to mildly painful procedures (England et al 1992; Daunt & Steffey 2002). They vary 
considerably in potency, depending on their alpha2-adrenoceptor selectivity (Virtanen et al 1985). 
Xylazine serves as the prototype and was the first alpha-2 adrenoceptor agonist approved for use in 
horses (Clarke & Hall 1969). The alpha 2-adrenoceptor agonists produce sedation and analgesia and 
potentiate the effects of other sedative-hypnotic and anaesthetic drugs by activating receptors in the 
locus coeruleus and spinal cord (Doze et al 1989) by two different mechanisms (Guo et al 1996). 
Stimulation of alpha 2-adrenoceptors in the locus coeruleus (A6 area) hyperpolarizes neurons and 
inhibits norepinephrine and dopamine storage and release. These effects decrease the discharge rate 
of locus coeruleus neurons, resulting in sedation, analgesia, and muscle relaxation. Conversely, 
dampening of locus coeruleus activity disinhibits activity in the adjacent cell bodies of A5 and A6 
areas, resulting in increased release or norepinephrine from their terminal in the dorsal horn, which 
in turn produces peripheral analgesia (Gaynor Muir 2009). Alpha2-Adrenoceptor agonists decrease 
central nervous system (CNS) sympathetic output and peripheral sympathetic tone (Schmitt et al 
1970). Parasympathetic (vagal) tone is initially increased as a result of transient increases in arterial 
blood pressure and increases in baroreceptor sensitivity (Lemke 2007). Most alpha 2-adrenoceptors 
agonists, especially xylazine, also produce some degree of alpha1-adrenoceptor activation, although 
the more selective alpha 2-adrenoceptor agonists (detomidine, medetomidine, dexmedetomidine) 
are relatively devoid of this effect. Interestingly, large (pharmacological) doses of alpha 2-
adrenoceptor agonists, including dexmedetomidine, produce minimum sedation initially, followed 
by a much longer period of pronounced sedation. This response is believed to be caused by 
activation of CNS alpha 1-adrenoceptors, which are known to functionally antagonize the hypnotic 
effects of alpha 2-adrenoceptor agonists (Guo et al 1991). Other neuromodulators, including 
endogenous opioids, purines, and cannabinoids, are speculated to be important contributors to the 
CNS effects of alpha 2-adrenoceptor agonists and are believed to be responsible for synergistic and 
additive interactions when alpha 2-adrenoceptor agonists are coadministered with opioid analgesics 
(Tham et al 2005). The alpha 2-adrenoceptor agonists can be antagonized by a variety of alpha 2-
adrenoceptor antagonists, including atipamezole (ATZ), tolazoline, and yohimbine (Yashamita et al 
1996). This propriety makes alpha2-agonists the best choice for sedation and antagonism during 
lameness investigation. In the past the use of ATZ has been reported after sedation with 
medetomidine (Virtanen 1989) and xylazine (Luna et al 1992). In another study 100 µg/kg of ATZ 
and 160 µg/kg were used in order to antagonize respectively the effect of 10 µg/kg and 20µg/kg of 
detomidine administered intravenously (Ramseyer et al 1998). In these studies was noticed a 
complete antagonism of the sedative effects on blood pressure, heart rate (HR) and behaviour, even 
though a residual sedative effect was still present. Furthermore 30 minutes after the ATZ had been 
administered some signs of sedation were reappearing. Due to the different results obtained,  a new 
study was planned using previously proven scales of sedation in order to extrapolate objective data. 
The more selective alpha-2 agonist currently available for use in equine medicine is 
dexmedetomidine, the active isomer of the detomidine (racemic mixture of equal parts of two 
optical enantiomers, dextro and levomedetomidine). Complete antagonism after dexmedetomidine 
administration was obtained in people (Karrhuvaara 1991), in cats (Granholm et al 2006) and in 
dogs (Granholm et al 2007). These encouraging results obtained in different species made us 
postulate that a complete antagonism could have been possible in the horse.   
As general matter, this study will be introduced by a short description of the orthopaedic 
examination of the horse, including history, static (conformation and palpation) and dynamic 
assessment (manipulation, diagnostic analgesia) and by a review of the pharmacological and 
clinical effects of the two drugs used (dexmedetomidine-atipamezole).    
  
ORTHOPAEDIC EXAMINATION OF THE HORSE 
 
Orthopaedic examination of the horse begins with collection of the history (anamnesis) from the 
owner and/or trainer. The importance of a detailed clinical history, cannot be overemphasized. 
Information is divided into two categories: basic facts necessary for every horse, and additional 
information from questions tailored to the specific horse. The veterinarian must understand the 
breed, use, and level of competition of each horse, because prognosis varies greatly among different 
types of sports horses. First hand experience of the particular type of sports horse being examined is 
useful but is not essential. Clinicians must understand the language associated with the particular 
sporting event, and this may be a challenge. For some sporting events, understanding the clinical 
history and having the ability to ask the right questions are like speaking a different language. The 
veterinarian must seek out as much information as possible, particularly if the problem is complex 
or not readily apparent. Videotapes are useful, particularly if the gait deficit, behavioural problem, 
or any other circumstances necessary to elicit the suspected lameness cannot be duplicated during 
the examination. Paraprofessionals working with the horse provide useful information, but not 
every- one may agree about the source of the problem, and in some instances diplomacy is key to 
negotiating among concerned individuals. 
 
The second part of the lameness investigation is the static assessment that involves assessment of 
conformation and palpation. 
 
The thought that the way a horse is conformed determines the way it moves is well accepted. The 
relationship of conformation, especially of the distal extremities, and lameness also is well 
recognized. “Conformation determines the shape, wear, flight of the foot, and distribution of 
weight”(Adams 1957). Veterinarians often are asked to comment on conformation during lameness 
and prepurchase examinations, especially with regard to the suitability of the horse to perform the 
intended task. In some instances, as in the case of presale yearling evaluations, the veterinarian’s 
opinion is paramount, and purchase is contingent on judgment of the yearling’s potential to perform 
as a racehorse, given its conformation, or in some instances its conformational faults. “It is by a 
study of conformation that we assign to a horse the particular place and purpose to which he is best 
adapted as a living machine and estimate his capacity for work, and the highest success in this 
connection will be best attained by the judicious blending of practice with science” (Belloy 1996). 
Evaluation of conformation and its influence on lameness is based largely on observation, 
experience, and pattern recognition. Recognizing desirable conformational traits in horses suited for 
a particular sporting activity and learning when to overlook a minor fault that has little clinical 
relevance are important.  
 
Palpation is an important part of a lameness examination. In some sports horses, it becomes more 
important because, for example, suspensory desmitis often is not associated with overt lameness but 
may compromise performance.  
The veterinarian must develop a system to evaluate comprehensively all parts of the 
musculoskeletal system. Each forelimb should be palpated followed by neck, back, pelvic regions, 
and then the hindlimbs. Each limb should be assessed when bearing weight and then again with the 
limb elevated from the ground. Deep palpation is used to describe direct, digital palpation, with the 
limb in an elevated position.  
If time permits, palpation should be completed before the horse is moved, because if the lame limb 
is identified first, the other limbs may be overlooked and compensatory problems may be missed. 
Comprehensive palpation may allow the clinician to make predictions about lameness, to “read” the 
horse. Palpation before exercise also facilitates identification of localized heat or swelling, because 
limb temperature increases with exercise, and swelling often decreases. 
 
The third part of the lameness examination is constituted of assessment of dynamic assessment, 
manipulation (when appropriate) and diagnostic analgesia. 
 
Although all parts of the lameness examination are important, the key is the determination of the 
limb or limbs involved. This is best performed with the horse moving at the trot on straight line, 
lunge and on different surface. Different grading systems have been proposed in order to 
objectively assess the degree of lameness (Tab.1 and 2). 
 
Flexion or other manipulative tests often are used to induce or exacerbate lameness during lameness 
or prepurchase examinations.  
 
Despite the many technological advances in equine sports medicine over the past three decades, 
diagnostic analgesia arguably remains the most valuable tool in the equine clinician’s arsenal to 
localize the source of pain causing lameness. Although the technique requires a thorough 
understanding of anatomy, basic technical skill, and clinical experience, the equipment and expense 
are minimal. In addition, diagnostic analgesia can be performed on site, with the outcome 
immediately obvious.  
 Degree Lameness 
0 Lameness not perceptible under any circumstances. 
1 Lameness is difficult to observe and is not consistently apparent, regardless of 
circumstances (e.g. under saddle, circling, inclines, hard surface, etc.). 
2 Lameness is difficult to observe at a walk or when trotting in a straight line but 
consistently apparent under certain circumstances (e.g. weight-carrying, circling, inclines, 
hard surface, etc.). 
3 Lameness is consistently observable at a trot under all circumstances. 
4 Lameness is obvious at a walk. 
5 Lameness produces minimal weight bearing in motion and/or at rest or a complete 
inability to move. 
 
Tab. 1 – AAEP lameness assessment scale. 
 
 
 
Degree Lameness 
0 No lameness observed   
1 Lameness is difficult to observe. The lameness is inconsistent, and might only be observed 
while the horse is turned  
2 Lameness difficult to detect at the walk or at the trot on a straight line. Constant lameness 
when the horse is turned  or under similar ‘stress’   
3 Lameness difficult to detect at the walk but consistent at the trot regardless of the 
circumstances   
4 Lameness consistent at the walk and trot regardless of the circumstances   
5 Obvious lameness with marked head-nod at the trot   
6 Marked head-nod at the walk, and has problems with trotting   
7 Lameness is marked with minimal weight bearing. The horse is reluctant to move (the 
horse ‘carries the leg’)   
 
Tab. 2 – Lameness grading system proposed by Lindegaard et al in 2010. 
  
SEDATION OF THE HORSE 
 
ASSESSMENT OF THE SEDATION 
 
During the past years different ways of assessing the degree of sedation have been proposed. Those 
most commonly used in human medicine are three. The Bispectral Index Scale is an objective scale 
based on electroencephalography assessment. The Visual Analogue Scale (VAS) where a value 
between 0 and 10 is given (zero corresponds to the maximum degree of sedation and ten to an 
awake horse). The Sedation-Agitation Scale (SAS) allocates the patient to a behavioural category 
ranging from 1 to 7 (Riker et al 2001) (Tab. 3). 
 
Score Category Description 
1 Dangerous agitation Pulling at endotracheal tube, trying to remove catheters, 
climbing over bedrail, striking at staff, thrashing side-to-side  
2 Very agitated  Does not calm despite frequent verbal reminding of limits, 
requires physical restraints, biting endotracheal tube  
3 Agitated  Anxious or mildly agitated, attempting to sit up, calms down 
on verbal instructions  
4 Calm, cooperative  Calm, easily arousable, follows commands  
5 Sedated  Difficult to arouse, awakens to verbal stimuli or gentle shaking 
but drifts off again, follows simple commands  
6 Very sedated  Arouses to physical stimuli but does not communicate or 
follow commands, may move spontaneously  
7 Unarousable Minimal or no response to noxious stimuli, does not 
communicate or follow commands  
Tab. 3 – Sedation score proposed by Riker et al, 2001. 
 
This scoring system was then replaced by the Richmond Agitation-Sedation Scale (Tab. 4) with the 
scores ranging from -5 to +4. In this system four scores described the state of anxiety or excitement 
(from 1 restless to 4 aggressive) one to the normal patient (0) and 5 scores described the depth of 
sedation obtained (from 1 quiet to 5 unresponsive to stimuli). The assessment protocol for this 
system included visual assessment of the patient, assessment of the response to vocal and noxious 
stimuli (Rassin et al 2007; Khan et al 2012; Sessler et al 2002).  
Score Term Description 
+4  Combative Overtly combative or violent; immediate danger to staff 
+3  Very 
agitation 
Pulls on or removes tube(s) or catheter(s) or has aggressive 
behaviour  
toward staff 
+2  Agitated Frequent non-purposeful movement or patient–ventilator 
dyssynchrony  
+1  Restless Anxious or apprehensive but movements not aggressive or 
vigorous  
0  Alert and 
calm 
 
-1  Drowsy Not fully alert, but has sustained (more than 10 seconds) 
awakening, with eye contact, to voice  
-2  Light sedation Briefly (less than 10 seconds) awakens with eye contact to voice  
-3  Moderate sedation Any movement (but no eye contact) to voice 
-4  Deep sedation No response to voice, but any movement to physical stimulation  
-5  Unarousable No response to voice or physical stimulation  
1. Procedure 
Observe patient. Is patient alert and calm (score 0)? Does patient have behaviour that is consistent with 
restlessness or agitation (score 1 to 4 using the criteria listed above, under DESCRIPTION)?  
2. If patient is not alert, in a loud speaking voice state patient’s name and direct patient to open eyes and look at 
speaker. Repeat once if necessary. Can prompt patient to continue looking at speaker. 
Patient has eye opening and eye contact, which is sustained for more than 10 seconds (score 1). Patient has eye 
opening and eye contact, but this is not sustained for 10 seconds (score 2). Patient has any movement in 
response to voice, excluding eye contact (score 3).  
3. If patient does not respond to voice, physically stimulate patient by shaking shoulder and then rubbing sternum 
if there is no response to shaking shoulder. Patient has any movement to physical stimulation (score 4). Patient 
has no response to voice or physical stimulation (score 5). 
Tab. 4 - Richmond Agitation-Sedation Scale 
 
When a horse is sedated there are different signs that can be noticed: lowering of the head, ptosis of 
the lower lip, ataxia, sway movement and in geldings/stallions penile exteriorization (Daunt 2002). 
Frequently the muscle relaxation of the nostrils and larynx produced stridor (Muir 1991). 
The height of the head over the ground has previously been used as a measure of the degree of 
sedation after alpha-2 agonists administration (England et al 1992). This method allows an 
objective assessment of the degree of the sedation, however no importance is given to the quality of 
the sedation. For this reason different ways of assessing the sedation have been developed. 
In another study that assessed the degree of the sedation other parameters were taken into account. 
These included the degree of muscle relaxation, the ataxia and the ability of completing a certain 
path assessing the time required to do so (Muir & Hubbell 2006). The height of the head was 
measured 5 min before the administration and at 5, 25, 45, 90 min after sedation with detomidine 
(0.02 mg/kg IV). The time required for the horses to complete a circuit with obstacles was the 
assessed 20 min before sedation and 10, 20, 25, 45, 60 e 90min. 
 Tab. 5 - Numerical rating scale (NRS) used to assess postural instability, ataxia during motion, and 
response to tactile, visual and acoustic stimulation in horses (Ringer et al 2013). 
 
 A score between 0 and 4 was therefore assigned. With system zero corresponded to a horse able to 
complete the circuit without any difficulties and four to horses unable to complete the task. 
In other studies the heart rate, respiratory rate were also considered (Love et al 2011).  
One of the most recent studies a VAS was used to measure the height of the head from the ground 
and also the degree of ataxia when standing, walking and the response after acoustic stimuli (Ringer 
et al 2013). The heart, respiratory rate and temperature were recorded the morning when the study 
was performed. The scores on the numeric rating scale were then assigned to each patient in the 
different phases of the study (Tab. 5). 
After having assessed all the previous studies we deemed the study of Ringer et al the most 
appropriate in order to evaluate the degree of sedation in the present study. 
  
The experimental design was that of a random-
ized, crossover study, with a minimum time of
8 days between treatments. All the observations
were carried out by a single observer who was
unaware of the treatment administered.
Once baseline meas rements were complete ,
horses were sedated with a loading dose of xyla-
zine (1 mg kg)1) (Xylasol ad us. vet., Dr. E. Graeub
AG, Switzerland) or romifidine (80 lg kg)1)
(Sedivet, Boehringer Ingelheim France, France)
injected manually over 3 minutes throu h the
jugular venous catheter. Immediately following
the bolus dose administration, a CRI of
xylazine (0.69 mg kg)1 hour) or romifidine
(30 lg kg)1 hour) was started, and was continued
for 120 minutes. The infusions were delivered
through extension sets (Original Perfusor-Leitung
PE, B. Br un AG, Germany) by an nf ion pump
(Syramed, lSP6000, Arcomed AG, Switzerland)
situated outside of the box stable. Romifidine was
diluted into 0.9% saline (Chlorure de Sodium 0.9%
B. Braun, B. Braun Medical, France) so that equal
volumes could be used with both treatments for
loading dose and CRI.
The different variables were measured at different
time-points, but not all of them at any one time
point, in order to avoid a stimulation of one type
influencing the response to a different stimulation
(Table 2). Ataxia during motion was not assessed
during the first hour after loading dose application
to avoid potential accidents.
Frequency of urination and of obstructed respi-
ration (snoring) was noted.
Statistical analyses were performed using the
software packages SigmaStat! 3.5 (SigmaStat! 3.5,
Systat Software GmbH, Germany) and R (R devel-
opment Core Team 2012, Austria). Normality was
tested by plotting data graphically and by the
Kolomogrov-Smirnov normality test.
A two way repeated measures ANOVA followed by
a generalized linear mixed model was used to study
the differences between treatments and over time.
A Holm-Sidak versus control (B) was used as post hoc
test. Whenever significance was detected, a Wilco-
xon Signed Rank test was used as confirmation.
A Wilcoxon Signed Rank Test was used to
compare the two treatments regarding frequency
of urination. Significance was set at p < 0.05.
Results are pre ented as median, range and
interquartile range (IQR).
Results
The experiments were performed in the wintertime
in order to avoid disturbance of horses due to
insects. One horse had to be excluded because the
alpha2-adrenergic agonist infusion did not run for
10 minutes because the line was frozen.
With xylazine treatment, compared to romifidine,
the HHAG was significantly lower 10 minutes
(p = 0.008) after starting loading dose adminis-
tration and, after the infusion had ceased at
Table 1 Numerical rating scales (NRS) used to assess postural instability, ataxia during motion, and response to tactile,
visual and acoustic stimulation in horses
NRS
Postural
Instability
Ataxia during
motion Touch Visual Acoustic
0 No signs of
instability,
stable
No signs of
instability
Exaggerated reaction
after smooth pressing:
fast movement of the leg
Undiminished response,
animal moves away
vigorously
Undiminished
response, animal
turns vigorously
1 Stable but
swaying
slightly
No ataxia when
straight, slight
ataxia when
turning
Animal elevates
the front leg after
normal pressure
Muted response,
subdued reaction
and movements
Muted response,
subdued reaction
and movements
(turns slowly)
2 Swaying
clearly
Ataxia when
walking straight
Slightly diminished
response with
normal to strong
pressing
Reaction significantly
subdued (elevates
head slightly)
No appreciable
response, but
evidence of hearing
(movement of ears)
3 Nearly falling
down
Severe ataxia,
risk of falling
down
No response even
with strong
pressing
No signs of visual
arousal
No sign of noise
recognition
4 Horse falling
down
Horse falling down
Xylazine versus romifidine CRI in horses SK Ringer et al.
" 2012 The Authors. Veterinary Anaesthesia and Analgesia
" 2012 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesiologists, 40, 157–165 159
ALPHA 2-AGONISTS 
 
Alpha-2 agonists, such as xylazine, clonidine, romifidine, detomidine, medetomidine, and 
dexmedetomidine, are potent analgesic drugs that also induce physiologic and behavioural changes, 
such as hypertension, bradycardia, atrioventricular block, excessive sedation and ataxia, all of 
which can potentially limit their systemic use as analgesics in some clinical cases. Therefore it is of 
utmost importance to know the individual properties of each of the alpha-2 agonists to select the 
ideal drug for each clinical condition, based on the duration of action of analgesia and behavioural 
changes.  
Since the last review on this subject (Daunt & Steffey 2002), the use of medetomidine and 
dexmedetomidine has been introduced for equine anaesthesia/analgesia, and although not approved 
in this species, their increased specificity for alpha-2 receptors may offer some potential advantages 
over the traditional alpha-2 agonists. Similarly, other routes of administration and benefits of alpha-
2 agonists are recognized in the human and laboratory animal literature, which may prove useful in 
the equine patient if validated in the near future. 
 
 
Fig. 1 - Adrenergic receptors are subdivided into alpha and beta. Both alpha and beta are further 
classified into alpha-1, alpha-2, beta-1, and beta-2. Alpha receptors are located post- synaptically 
(alpha-1 and alpha-2) and presynaptically (alpha-2) at sympathetic neuroeffector junctions of many 
organs.  
 
Adrenergic receptors are subdivided into alpha and beta. Both alpha and beta are further classified 
into alpha-1, alpha-2, beta-1, and beta-2. Alpha receptors are located postsynaptically (alpha-1 and 
alpha-2) and presynaptically (alpha-2) at sympathetic neuroeffector junctions of many organs (Fig. 
Activation of the presynaptic alpha-2 receptor inhibits the release of norepinephrine
(NE) into the synaptic cleft and autoregulates its actions on the effector cells. The net
ffect of activation of alpha-2 adrenergic rec ptors is modulation of sympathetic
nervous system activity by inhibition of NE. Manifestations of this response include
decreased cardiac output due to decreased inotropy and decreased heart rate, as
well as a reduction in systemic vascular resistance. Conversely, the activation of post-
synaptic alpha receptors mediates an increase in systemic vascular resistance.
Actions at centrally located alpha-2 adrenergic receptors mediate sedation, anxioly-
sis, analgesia, and hypnosis. It has also been shown that the alpha-1 agonistic activity
can reduce the alpha-2 mediated analgesia, and it has been suggested that coadmin-
istration of an alpha-1 antagonist (prazosin) with the alpha-2 agonist may enhance
analgesic potency.2 The alpha-2/alpha-1 selectivity for alpha-2 agonists is 160 for
xylazine, 220 for clonidine, 260 for detomidine, and 1620 for medetomidine or dexme-
detomidine,3 and is unknown for romifidine but higher than for xylazine. As selectivity
for alpha-2 receptors increases, the greater specificity results in higher potency, espe-
cially at central alpha-2 adrenoceptors. Medetomidine is considered 10 times, 7 times,
and 6 times more potent than xylazine, clonidine, and detomidine, respectively.4
However, other nonadrenergic mechanisms are probably implicated in analgesic
actions of alpha-2 agonists because the rank potency order of spinal depressant
actions on in vitro preparations is the same as their rank analgesic potencies in
vivo: dexmedetomidine (medetomidine) > clonidine > detomidine > xylazine,5–7 which
does not coincide precisely with alpha-2 agonists of intermediate specificity. It has
also been suggested that differences between the actions of these ligands are attrib-
utable to an action at alpha-1 receptors.5
Fig. 1. Adrenergic receptors are subdivided into alpha and beta. Both alpha and beta are
further classified into alpha-1, alpha-2, beta-1, and beta-2. Alpha receptors are located post-
synaptically (alpha-1 and alpha-2) and presynaptically (alpha-2) at sympathetic neuroeffec-
tor junctions of many organs.
Valverde516
1). Beta receptors are located postsynaptically and in general mediate decreased activity of the 
effector cells (beta-2: vasodilation, bronchodilation, uterine relaxation) or increased activity (beta-1: 
heart automaticity and contractility). Postsynaptic activation of alpha receptors mediate increased 
activity of the effector cells.  
Activation of the presynaptic alpha-2 receptor inhibits the release of norepinephrine (NE) into the 
synaptic cleft and autoregulates its actions on the effector cells. The net effect of activation of 
alpha-2 adrenergic receptors is modulation of sympathetic nervous system activity by inhibition of 
NE. Manifestations of this response include decreased cardiac output due to decreased inotropy and 
decreased heart rate, as well as a reduction in systemic vascular resistance. Conversely, the 
activation of post-synaptic alpha receptors mediates an increase in systemic vascular resistance. 
Actions at centrally located alpha-2 adrenergic receptors mediate sedation, anxiolysis, analgesia, 
and hypnosis. It has also been shown that the alpha-1 agonistic activity can reduce the alpha-2 
mediated analgesia, and it has been suggested that coadministration of an alpha-1 antagonist 
(prazosin) with the alpha-2 agonist may enhance analgesic potency (Gil et al 2009). The alpha-
2/alpha-1 selectivity for alpha-2 agonists is 160 for xylazine, 220 for clonidine, 260 for detomidine, 
and 1620 for medetomidine or dexmedetomidine (Tab. 6) (Virtanen et al 1988), and is unknown for 
romifidine but higher than for xylazine. As selectivity for alpha-2 receptors increases, the greater 
specificity results in higher potency, especially at central alpha-2 adrenoceptors. Medetomidine is 
considered 10 times, 7 times, and 6 times more potent than xylazine, clonidine, and detomidine, 
respectively (Virtanen & MacDonald 1985). However, other non-adrenergic mechanisms are 
probably implicated in analgesic actions of alpha-2 agonists because the rank potency order of 
spinal depressant actions on in vitro preparations is the same as their rank analgesic potencies in 
vivo: dexmedetomidine (medetomidine) > clonidine > detomidine > xylazine (Faber et al 1998), 
which does not coincide precisely with alpha-2 agonists of intermediate specificity. It has also been 
suggested that differences between the actions of these ligands are attributable to an action at alpha-
1 receptors.  
 
 
 
Tab. 6 – Alpha 2: Alpha 1 Selectivity 
 
192 Chapter 10  N Anxiolytics, Nonopioid Sedative-Analgesics, and Opioid Analgesics
or become mildly depressed. Some horses develop pica for 
brief periods. No other serious side effects or toxicities 
have been reported after a ministration of diazepam, mid-
azolam, or climazolam to horses.
NONOPIOID SEDATIVE-ANALGESICS
Nonopioid sedative-analgesics are represented by a large 
number of compounds that produce anxiolysis and skeletal 
muscle relaxation and relieve pain in horses. Xylazine, deto-
midine, romifidine, and medetomidine, collectively referred 
to as D2-adrenoceptor agonists, are favored for this purpose 
and have been investigated extensively in horses (see Table 
10-1).72-74 Other D2-adrenoceptor agonists, including dex-
medetomidine and clonidine, have been demonstrated to 
produce sedative-analgesic effects in horses but have not 
become popular in equine practice.75,76
All D2-adrenoceptor agonists are highly soluble in w ter 
and available as aqueous solutions for injection. They vary 
considerably in potency, depending on th ir D2-adrenocep-
tor selectivity (Box 10-2).77 Xylazine serves as the prototype 
and was the first D2-adrenoceptor agonist approved for use 
in horses.78 Detomidine and medetomidine are more potent 
than romifidine, and all three are more potent than xylazine 
in horses.74,79 Interestingly, differences exist among species 
regarding the sedative effects of D2-adrenoceptor agonists. 
Approximately one tenth the dose of xylazine is required to 
produce sedation in cattle and steers compared to horses; but 
similar doses of detomidine, medetomidine, and romifidine 
are used in both species.80 The D2-adrenoceptor agonists pos-
sess many of the qualities required for an ideal preanesthetic 
drug, including predictability, anxiolysis, marked sedation, 
stupor, and indiffer nce to mildly painful procedures (see 
Box 10-1).72-74 They are frequently administered as mono-
therapy or in onjunction with ace romazine or opioids 
to facilitate standing medical procedures and as preanes-
thetic medication.74 They ar  also dministered as sedative 
or analgesic adjuncts to intravenous or inhalant anesthesia 
to decrease anesthetic requirements (see Chapter 13).81,82 
Finally, D2-adrenoceptor agonists can be administered by epi-
dural or subarachnoid routes to produce local or segmental 
spinal analgesia (see Chapter 11).83
Mechanism of Action
Activation of D (D1 and D2)-adrenoceptors produces varied 
pharmacologic effects (see Table 10-3).77,84 The D2-adrenocep-
tor agonists produce sedation and analgesia and potentiate 
the effects of other sedative-hypnotic and anesthetic drugs 
by activating D2-receptors in the locus ceruleus and spinal 
cord.84 Stimulation of D2-adrenoceptors in the CNS hyperpo-
larizes neurons and inhibits norepinephrine and dopamine 
storage and release. These effects decrease the discharge 
rate of  c ntral nd peripheral neurons, resulting in sedation, 
analgesia, and muscle relaxation. D2-Adrenoceptor agonists 
d cr ase CNS sympathetic output and peripheral sympathetic 
tone.85 Parasympathetic (vagal) tone is increased initially as 
a result f transi nt increases in arterial blood pressure and 
increases in baroreceptor sensitivity.80 Most D2-adrenoceptor 
agonists, especially xylazine, also produce some degree of 
Dl-adrenoceptor activation, although the more selective D2-adrenoceptor agonists (detomidine, medetomidine, 
dexmedetomidine) are relatively devoid of this effect (see 
Box 10-2). Interestingly, large (pharmacological) doses of 
D2-adrenoceptor agonists, including dexmedetomidine, pro-
duce minimum sedation initially, followed by a much lon-
ger period of pronounced sedation. This response is believed 
to be caused by activation of CNS D1-adrenoceptors, which 
are known to functionally antagonize the hypnotic effects of 
D2-adrenoceptor agonists.86 Other neuromodulators, includ-
ing endogenous opioids, purines, and cannabinoids, are 
speculated to be important contributors to the CNS effects 
of D2-adrenoceptor agonists and are believed responsible for 
synergistic and additive interactions when D2-adrenocep-
tor agonists are coadministered with opioid analgesics.87  
The D2-adrenoceptor agonists can be antagonized by a vari-
ety of D2-adrenoceptor antagonists, including atipamezole, 
tolazoline, and yohimbine (see Table 10-2).88-90
Applied Pharmacology
The D2-adrenoceptor agonists produce relatively predict-
able sedation and muscle relaxation. They all produce dose-
dependent sedation, increases in horses’ tolerance to painful 
Table 10–3.  Location and function of al- and a2-
adrenoceptors
Receptor type and 
location
 
Function
a1
Central nervous  
system
Increase awareness and activity
Heart Increase force of contraction 
and sensitization of 
the myocardium to 
catecholamines during 
halothane anesthesia
Smooth muscle Vasoconstriction
Liver Glycogenolysis; gluconeogenesis
a2
Central nervous 
system
Decreases norepinephrine and 
dopamine release causing 
sedation and cardiopulmonary 
depression
Sympathetic nerve  
terminal
Inhibition of norepinephrine 
release
Cholinergic neurons Inhibition
Heart Decrease norepinephrine release
Smooth muscle Vasoconstriction
Gut Reduced tone and propulsive 
activity
Pancreatic islet cells Inhibition of insulin release
Platelets Aggregation
Fat Inhibition of lipolysis (clonidine)
Box 10–2 a2:a1-Selectivity
Drug a2:a1
Xylazine 160:1
Detomidine 260:1
Medetomidine 1620:1
Romifidine 340:1
Clonidine 220:1
Alpha-2 agonists activate 3 distinct subtypes of alpha-2 adrenergic receptors: alpha-2A, alpha-2B, 
and alpha-2C. Despite the higher affinity of detomidine and medetomidine for the alpha-2 receptors 
compared with xylazine, the former drugs cannot discriminate between the different receptor 
subtypes (Schwartz & Clark 1998) . The alpha-2A adrenergic receptor is the primary mediator 
involved in alpha-adrenergic spinal analgesia for endogenous NE as well as exogenous adrenergic 
agonists (Stone et al 1997). These receptors are G-protein–coupled receptors that decrease neuronal 
excitation by several mechanisms, including opening of rectifying potassium channels, decrease of 
presynaptic calcium influx, and inhibition of adenylyl cyclase (Stone et al 1997). The activation of 
alpha-2 receptors by an agonist induces the receptor to interact with a Gi type of G protein and 
inhibits the actions of adenylyl cyclase, decreasing the synthesis of cyclic adenosine mono- 
phosphate from adenosine triphosphate. Besides analgesia, the alpha-2A receptor promotes 
hypnosis, sedation, inhibition of insulin secretion, neuroprotection, and sympatholysis (Fagerholm 
et al 2008). Alpha-2B receptors are involved in spinal analgesia and vasoconstriction of peripheral 
arteries (Philipp et al 2002). Alpha-2C receptors are involved in pain modulation, mood- and 
stimulant-induced locomotor activity, regulation of epinephrine outflow from the adrenal medulla, 
and modulation of cognition.  
 
 
Tab. 7 – Location and function of alpha-1 and -2 adrenoceptors. 
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or become mildly depressed. Some horses develop pica for 
brief periods. No other serious side effects or toxicities 
have been reported after administration of diazepam, mid-
azolam, or climazolam to horses.
NONOPIOID SEDATIVE-ANALGESICS
Nonopioid sedative-analgesics are represented by a large 
number of compounds that produce anxiolysis and skeletal 
muscle relaxation and relieve pain in horses. Xylazine, deto-
midine, romifidine, and medetomidine, collectively referred 
to as D2-adrenoceptor agonists, are favored for this purpose 
and have been investigated extensively in horses (see Table 
10-1).72-74 Other D2-adrenoceptor agonists, including dex-
medetomidine and clonidine, have been demonstrated to 
produce sedative-analgesic effects in horses but have not 
become popular in equine practice.75,76
All D2-adrenoceptor agonists are highly soluble in water 
and available as aqueous solutions for injection. They vary 
considerably in potency, depending on their D2-adrenocep-
tor selectivity (Box 10-2).77 Xylazine serves as the prototype 
and was the first D2-adrenoceptor agonist approved for use 
in horses.78 Detomidine and medetomidine are more potent 
than romifidine, and all three are more potent than xylazine 
in horses.74,79 Interestingly, differences exist among species 
regarding the sedative effects of D2-adrenoceptor agonists. 
Approximately one tenth the dose of xylazine is required to 
produce sedation in cattle and steers compared to horses; but 
similar doses of detomidine, medetomidine, and romifidine 
are used in both species.80 The D2-adrenoceptor agonists pos-
sess many of the qualities required for an ideal preanesthetic 
drug, including predictability, anxiolysis, marked sedation, 
stupor, and indifference to mildly painful procedures (see 
Box 10-1).72-74 They are frequently administered as mono-
therapy or in conjunction with acepromazine or opioids 
to facilitate standing medical procedures and as preanes-
thetic medication.74 They are also administered as sedative 
or analgesic adjuncts to intravenous or inhalant anesthesia 
to decrease anesthetic requirements (see Chapter 13).81,82 
Finally, D2-adrenoceptor agonists can be administered by epi-
dural or subarachnoid routes to produce local or segmental 
spinal analgesia (see Chapter 11).83
Mechanism of Action
Activation of D (D1 and D2)-adrenoceptors produces varied 
pharmacologic effects (see Table 10-3).77,84 The D2-adrenocep-
tor agonists produce sedation and analgesia and potentiate 
the effects of other sedative-hypnotic and anesthetic drugs 
by activating D2-receptors in the locus ceruleus and spinal 
cord.84 Stimulation of D2-adrenoceptors in the CNS hyperpo-
larizes neurons and inhibits norepinephrine and dopamine 
storage and release. These effects decrease the discharge 
rate of  central and peripheral neurons, resulting in sedation, 
analgesia, and muscle relaxation. D2-Adrenoceptor agonists 
decrease CNS sympathetic output and peripheral sympathetic 
tone.85 Parasympathetic (vagal) tone is increased initially as 
a result of transient increases in arterial blood pressure and 
increases in baroreceptor sensitivity.80 Most D2-adrenoceptor 
agonists, especially xylazine, also produce some degree of 
Dl-adrenoceptor activation, although the more selective D2-adrenoceptor agonists (detomidine, medetomidine, 
dexmedetomidine) are relatively devoid of this effect (see 
Box 10-2). Interestingly, large (pharmacological) doses of 
D2-adrenoceptor agonists, including dexmedetomidine, pro-
duce minimum sedation initially, followed by a much lon-
ger period of pronounced sedation. This response is believed 
to be caused by activation of CNS D1-adrenoceptors, which 
are known to functionally antagonize the hypnotic effects of 
D2-adrenoceptor agonists.86 Other neuromodulators, includ-
ing endogenous opioids, purines, and cannabinoids, are 
speculated to be important contributors to the CNS effects 
of D2-adrenoceptor agonists and are believed responsible for 
synergistic and additive interactions when D2-adrenocep-
tor agonists are coadministered with opioid analgesics.87  
The D2-adrenoceptor agonists can be antagonized by a vari-
ety of D2-adrenoceptor antagonists, including atipamezole, 
tolazoline, and yohimbine (see Table 10-2).88-90
Applied Pharmacology
The D2-adrenoceptor agonists produce relatively predict-
able sedation and muscle relaxation. They all produce dose-
dependent sedation, increases in horses’ tolerance to painful 
Table 10–3.  Location and function of al- and a2-
adrenoceptors
Receptor type and 
location
 
Function
a1
Central nervous  
system
Increase awareness and activity
Heart Increase force of contraction 
and sensitization of 
the myocardium to 
catecholamines during 
halothane anesthesia
Smooth muscle Vasoconstriction
Liver Glycogenolysis; gluconeogenesis
a2
Central nervous 
system
Decreases norepinephrine and 
dopamine release causing 
sedation and cardiopulmonary 
depression
Sympathetic nerve  
terminal
Inhibition of norepinephrine 
release
Cholinergic neurons Inhibition
Heart Decrease norepinephrine release
Smooth muscle Vasoconstriction
Gut Reduced tone and propulsive 
activity
Pancreatic islet cells Inhibition of insulin release
Platelets Aggregation
Fat Inhibition of lipolysis (clonidine)
Box 10–2 a2:a1-Selectivity
Drug a2:a1
Xylazine 160:1
Detomidine 260:1
Medetomidine 1620:1
Romifidine 340:1
Clonidine 220:1
Alpha-2 agonists administered intravenously (IV) in clinical doses have elimination half-lives of 
less than 1.5 hours and relatively small volumes of distribution of 0.5 to 1.6 L/kg. Elimination half-
lives are slightly longer when administered intramuscularly (IM) (Grimsroad et al 2009).  
Based on similar sedative effects, equipotent IV doses of these drugs are: 5 to 10 mg/kg of 
medetomidine, 3.5 mg/kg of dexmedetomidine, 20 to 40 mg/kg of detomidine, 80 to 120 mg/kg of 
romifidine, 1 mg/kg of xylazine, and 25 mg/kg of clonidine.  
The analgesic effects of alpha-2 agonists result from spinal and supraspinal actions (Tab. 7). Alpha-
2 receptors are found on primary afferent terminals in peripheral and spinal nerve endings, at the 
level of the superficial laminae of the dorsal horn of the spinal cord, and centrally in the brainstem. 
Therefore, administration of alpha-2 agonists in any of these locations offers the possibility of 
analgesic actions, which may also be synergistic with other groups of analgesic drugs. There is 
good evidence for primary analgesic actions as well as opioid-sparing effects; for example, epidural 
coadministration of alpha-2 agonists in combination with opioids contribute to the potency and 
efficacy of opioids and allow for administration of lower doses to achieve analgesia (Stone et al 
1997).  
In the horse, systemic and epidural administration is currently the most common routes for alpha-2 
agonists (Table 2), but in humans the intra-articular, intercostal infiltration, and intravenous 
regional routes have also been used (Al-Metwalli et al 2008).  
The most commonly recognized cardiovascular effects of alpha-2 agonists are a decrease in heart 
rate, an initial increase in systemic vascular resistance and blood pressure followed by a decrease, 
an initial decrease in cardiac output and respiratory rate followed by recovery to baseline, and 
transient decreases in PaO2 (Bettschart-Wolfensberger et al 2005). The biphasic effects on blood 
pressure are caused by initial increases in vascular resistance from postsynaptic alpha-2B receptor 
stimulation that induces hypertension, followed by decreased sympathetic discharge from 
presynaptic alpha-2A receptor stimulation that decreases NE release and presynaptic alpha-2C 
receptor stimulation that decreases epinephrine release from the adrenal glands, resulting in a 
decrease in vascular resistance and blood pressure (Knaus 2007). The use of higher doses of alpha-2 
agonists results in a more prolonged increase in vascular resistance and as a result cardiac output 
can be more adversely affected, resulting in hypotension despite the increased vascular resistance.  
Reported sedative effects of alpha-2 agonists in horses include decreased awareness, ptosis of the 
head, lower lip, and eyelids, ataxia, and a wide stance, and are mediated through alpha-2A receptors 
(Knaus 2007). 
Both sedative and physiologic effects of alpha-2 agonists have been correlated with plasma 
concentrations, and have been shown to be of greater magnitude and observed earlier after IV than 
after IM administration, although the duration of these changes may be shorter after IV 
administration (Mama et al 2009). It is not clear, however, whether the analgesic effects endure and 
correlate with the duration of the sedative and physiologic changes. Horses administered clonidine 
(25 mg/kg, IV) showed peak sedative and analgesic effects at 20 minutes and 30 minutes, 
respectively. Analgesia was assessed using a heat source to elicit hoof withdrawal reflexes and, 
despite lowering of the head associated with the sedation for up to 2.5 to 3 hours, significant 
analgesia was present for a shorter period (45 minutes) and was only considered submaximal at 
peak effect (Dirikolu et al 2006). In another study using a model of nociceptive withdrawal reflex 
(NWR) that limits the influence of the animal’s behaviour over analgesia, administration of 
equipotent IV doses of xylazine (1 mg/kg), detomidine (20 mg/kg), or romifidine (80 mg/kg) 
resulted in similar increases in thresholds to elicit the NWR in hind- and forelimbs and therefore 
equipotent analgesic effects (Rohrbach et al 2009). Analgesia peaked at 10 to 40 minutes after 
injection (first for xylazine and last for romifidine) and lasted 60 minutes for xylazine and 90 
minutes for detomidine, and was still present at 120 minutes for romifidine.34 Of note, sedation 
was significant and present for the duration of action of analgesia for xylazine and detomidine, but 
shorter (90 minutes) for romifidine (Rohrbach et al 2009). It seems from these studies that sedation 
and analgesia do not correlate, because one study reports shorter duration of analgesia than 
sedation20 and another study reports similar or more prolonged analgesia than sedation (Rohrbach 
et al 2009). Differences could be due to the properties of the individual alpha-2 agonist, the pain 
model used and site of nociceptive stimulation, stimulation that decreases NE release and 
presynaptic alpha-2C receptor stimulation that decreases epinephrine release from the adrenal 
glands, resulting in a decrease in vascular resistance and blood pressure. The use of higher doses of 
alpha-2 agonists results in a more prolonged increase in vascular resistance and as a result cardiac 
output can be more adversely affected, resulting in hypotension despite the increased vascular 
resistance.  
Reported sedative effects of alpha-2 agonists in horses include decreased awareness, ptosis of the 
head, lower lip, and eyelids, ataxia, and a wide stance, and are mediated through alpha-2A 
receptors.  
Both sedative and physiologic effects of alpha-2 agonists have been correlated with plasma 
concentrations, and have been shown to be of greater magnitude and observed earlier after IV than 
after IM administration, although the duration of these changes may be shorter after IV 
administration (Mama et al 2009). It is not clear, however, whether the analgesic effects endure and 
correlate with the duration of the sedative and physiologic changes. Horses administered clonidine 
(25 mg/kg, IV) showed peak sedative and analgesic effects at 20 minutes and 30 minutes, 
respectively. Analgesia was assessed using a heat source to elicit hoof withdrawal reflexes and, 
despite lowering of the head associated with the sedation for up to 2.5 to 3 hours, significant 
analgesia was present for a shorter period (45 minutes) and was only considered submaximal at 
peak effect (Dirikolu et al 2006). In another study using a model of nociceptive withdrawal reflex 
(NWR) that limits the influence of the animal’s behaviour over analgesia, administration of 
equipotent IV doses of xylazine (1 mg/kg), detomidine (20 mg/kg), or romifidine (80 mg/kg) 
resulted in similar increases in thresholds to elicit the NWR in hind- and forelimbs and therefore 
equipotent analgesic effects (Rohrbach et al 2009). Analgesia peaked at 10 to 40 minutes after 
injection (first for xylazine and last for romifidine) and lasted 60 minutes for xylazine and 90 
minutes for detomidine, and was still present at 120 minutes for romifidine (Rohrbach et al 2009). 
Of note, sedation was significant and present for the duration of action of analgesia for xylazine and 
detomidine, but shorter (90 minutes) for romifidine (Rohrbach et al 2009). It seems from these 
studies that sedation and analgesia do not correlate, because one study reports shorter duration of 
analgesia than sedation20 and another study reports similar or more prolonged analgesia than 
sedation (Rohrbach et al 2009). Differences could be due to the properties of the individual alpha-2 
agonist, the pain model used and site of nociceptive stimulation, alpha-2B receptors induces a 
gastroprotective effect by regulating gastric acid secretion and by inhibiting chemically (including 
NSAIDs) and physically (stress) induced gastric mucosal lesions (Gyires et al 2009). These benefits 
have not been evaluated in horses, and may prove useful in the colic horse that requires analgesia 
and has the predisposition for ulceration during hospitalization.  
Other considerations in horses administered alpha-2 agonists include the effects of these drugs on 
urine output. Alpha-2 agonists administered for sedation or during anaesthesia increase urine 
production, due to hyperglycemia from hypoinsulinemia (Valverde et al 2010) mediated through 
alpha-2A and -2C receptors (Peterhoff et al 2003), and due to a reduced secretion rate of arginine 
vasopressin (Alexander & Ivrine 2000). Patients should be monitored for urine output, hydration 
status, and comfort to avoid excessive bladder distension.  
Equipotent sedative doses of xylazine, romifidine, and detomidine increase intrauterine pressure for 
up to 30 minutes, as a result of increased uterine contractions. Electrical activity of the myometrium 
in the last trimester was observed to increase shortly (3–5 minutes) after IM injection of 20 or 40 
mg/kg of detomidine, but with no effect after 60 mg/kg, and lasted for 50 to 70 minutes without any 
adverse effects, and is therefore considered safe. In a study in which 8 mares during 10 pregnancies 
were administered detomidine (20 mg/kg, IV) once a week from days 14 to 60 of pregnancy and 
thereafter once a month until parturition, no side effects could be associated with administration, 
although 1 case of abortion was reported at 167 days. In a similar study, detomidine (15 mg/kg) 
administered to pregnant mares at 3-week intervals during the last trimester of pregnancy to assess 
maternal and fetal electrocardiographs showed reductions in heart rate in both, but alterations in 
conduction were detected only in mares, and there were no adverse outcomes of pregnancy. 
Another study has also demonstrated that despite systemic cardiovascular effects associated with 
alpha-2 agonists, it appears that based on colour Doppler ultrasonographic examinations local 
uterine and ovarian perfusion is not affected by detomidine or xylazine (Araujo & Ginther 2009) 
view of these findings, alpha-2 agonists are safe in pregnant animals, but close monitoring is 
advised.  
  
 ANTAGONISM OF ALPHA-2 ANTAGONIST AGENTS 
Even though alpha-2 agonists are safe drugs to use to sedate horses they still carry undesirable 
effects. These include ataxia, reduced gastrointestinal motility, hyperglycaemia, diuresis, increased 
uterine tone, sweating, muscle tremors, hypersalivation, penile protrusion (England & Clarke 1996) 
and tachypnoea in pyrexic horses (Kendall et al 2010).  
For this reason in past twenty years different drugs have been studied in order to antagonise these 
adverse effects. The decision to reverse the undesirable effects of α2-agonists could be based on an 
emergency situation, such as a horse collapsing or accidental overdose or on non-emergency 
clinically relevant situations such as a need to decrease the degree of ataxia.  
Tolazoline, yohimbine and ATZ (both central and peripheral acting α2-antagonists) are available in 
most countries and have been used to antagonise the α2-agonists in horses (Knych & Stanley 2014). 
Only tolazoline has been approved by the Food and Drug Administration (FDA) in the United 
States of America for reversal of xylazine effects in horses (Casbeer & Knych 2013). The 
Association of Racing Commissioners International (ARCI) (DiMaio Knych et al 2011a) classifies 
yohimbine as a Class 2 foreign substance. These pointers are important examples of legal 
considerations the veterinarian should keep in mind when considering administration of an α2-
antagonist to a horse. Veterinarians are encouraged to review the legal aspects of drug 
administration and rules set down by various associations regulating equine related competitions 
within their country of practice. Despite the highly prevalent off-label use of α2-antagonists in 
horses, there is a growing body of evidence to demystify their clinical effects as observed in horses.  
Tolazoline is a synthetic imidazoline derivative that antagonises α-adrenoceptors non-selectively 
(Casbeer & Knych 2013) and possesses histaminergic and cholinergic effects (El-Kammar & Gad 
2014). Tolazoline administered IV at 4 mg/kg bwt alone has the following pharmacokinetic profile: 
systemic clearance, steady state volume of distribution and terminal elimination half-life of 0.82 ± 
0.18 l/h/kg, 1.68 ± 0.38 l/kg and 2.69 ± 0.21 h, respectively (Casbeer & Knych 2013). The 
pharmacodynamic profile when tolazoline is administered alone demonstrates minimal behavioural 
responses; a decreased heart rate (most likely due to the increased sympathetic tone raising blood 
pressure and stimulating a baroreceptor mediated increase in vagal tone) with second degree 
atrioventricular blocks; an increase in blood glucose level and packed cell volume (increased 
sympathetic tone causing splenic contraction) and unchanged head-height-above-ground 
(measurement used to determine the level of sedation in horses) compared to baseline readings 
(Casbeer and Knych 2013). Tolazoline, in isoflurane-anaesthetised (Matthews et al 1995) or awake 
sedated ponies (Carroll et al. 1997), is effective in transiently antagonising detomidine-induced 
bradycardia without inducing arrhythmias or significant alterations to blood pressure. However, 
Matthews et al (1995) reported a significant decrease in the arterial partial pressure of oxygen; thus 
this must be considered when reversing detomidine- induced bradycardia with tolazoline in 
isoflurane-anaesthetised patients. Detomidine-induced sedation (assessed by measuring head-
height-above-ground that returns to baseline readings) is effectively antagonised with tolazoline 
(Carroll et al 1997). Transient sweating, hypersalivation and gingival hyperaemia may be noticed 
without overt signs of excitement. Blood glucose, cortisol and free fatty acid levels increase after 
administering tolazoline which suggests activation of a stress response. This is a clinically 
significant finding and antagonism of an α2-agonist with tolazoline may perpetuate an inappropriate 
stress response in horses that have undergone a surgical procedure or are in pain for some other 
reason (Carroll et al 1997). Stress, in the presence of pain, could culminate in a distressed patient 
which causes significant metabolic derangements not conducive to convalescence (Gaynor & Muir 
2009).  
Yohimbine is an indole alkaloid derived from several biological sources (bark of the Pausinystalia 
yohimbe tree and root of the Rauwolfia serpentina plant) that nonselectively antagonises α-
adrenoceptors in the horse (DiMaio Knych et al 2011a,b). Yohimbine has been shown at high doses 
to activate other receptor types including α1-adrenoceptors, dopamine and serotonin receptors and 
to inhibit monoamine oxidase (DiMaio Knych et al 2011b). Yohimbine administered at 0.12 mg/kg 
bwt IV alone has the following pharmacokinetic profile: systemic clearance, steady state volume of 
distribution and terminal elimination half-life of 13.6 ± 2.0 ml/min/kg, 3.2 ± 1.1 l/kg and 4.4 ± 0.9 
h, respectively, for a 2 compartment model (DiMaio Knych et al 2011a). Higher IV doses of 
yohimbine (0.2 and 0.4 mg/kg bwt) are associated with an increase in the plasma concentration that 
decreases in a dose-dependent manner, an increased volume of distribution and slower clearance. 
The elimination half-life remains consistent (DiMaio Knych et al 2011b). Detomidine increases the 
plasma concentration and decreases the clearance and volume of distribution of yohimbine (Knych 
et al 2012). This is clinically significant especially in racehorses where yohimbine is listed as an 
ARCI Class 2 foreign substance (DiMaio Knych et al 2011a); veterinarians would need to allow 
longe withdrawal periods. Pharmacodynamic effects of yohimbine alone are highly variable among 
horses, regardless of the dose administered (DiMaio Knych et al 2011b). Sedation or excitation 
(some horses may demonstrate rearing, striking, running in circles, generalised muscle tremors, 
agitation and exaggerated but mild excitation in horses exposed to sudden environmental 
stimulation) are typical pharmacodynamic effects that can be expected and usually resolve within 
1–2 h after yohimbine administration (DiMaio Knych et al 2011b). Transient cardiovascular and 
gastrointestinal effects such as an increase in heart rate with disappearance of atrioventricular 
blocks and an increase in borborygmi, respectively, may be present post yohimbine administration 
(DiMaio Knych et al 2011b). Yohimbine antagonism of detomidine has been studied in horses 
(DiMaio Knych et al 2012). Yohimbine is effective in antagonising detomidine- induced sedation, 
bradycardia and atrioventricular blocks. However, the pharmacodynamic response is variable 
among horses which include transient (approximately 10 min) vocalisation, increased arousal and 
return to normoglycaemia after detomidine-induced hyperglycaemia (DiMaio Knych et al 2012).  
There is no therapeutic indication or justification to use tolazoline (Casbeer & Knych 2013) or 
yohimbine (DiMaio Knych et al 2011b) as a sole agent to treat unsedated horses, due to their 
unpredictable pharmacodynamic effects.  
Two or more α2-adrenoceptor antagonists have been compared in a single study to antagonise α2-
agonists. The antagonistic properties of tolazoline and ATZ have been compared in detomidine-
sedated horses (Hubbell & Muir 2006) and donkeys (El-Kammar and Gad 2014). Both agents 
produce partial antagonism of detomidine-induced sedation and bradycardia. However, tolazoline 
antagonises detomidine-induced sedation more completely and hastens recovery compared to ATZ. 
The clinical effects of tolazoline last longer compared to ATZ in detomidine treated horses 
(Hubbell & Muir 2006; El-Kammar & Gad 2014). Apprehension may be anticipated in tolazoline-
treated horses while ATZ does not seem to demonstrate this clinical effect (Hubbell & Muir 2006). 
Knych and Stanley (2014) have recently reported on the antagonistic effects of tolazoline, 
yohimbine and ATZ on sublingually administered detomidine. Neither tolazoline nor Yohimbine, is 
able to completely return the head-height-above-ground measurements, despite the effect being 
short-lived (5 min). Yohimbine transiently antagonises detomidine-induced bradycardia to baseline 
values (pre detomidine administration), while tolazoline demonstrates a slight transient increase in 
heart rate above baseline values. ATZ mildly increases the heart rate without returning it to 
baseline. Tolazoline increased the packed cell volume, unlike yohimbine and ATZ which had no 
effect on it. The detomidine-induced hyperglycaemia is antagonised by yohimbine (return to 
baseline values), worsened by tolazoline (increase in hyperglycaemia) and ATZ demonstrates no 
effect on blood glucose level (Knych & Stanley 2014). The antagonistic properties of tolazoline and 
yohimbine have been compared in xylazine sedated horses (Kollias-Baker et al 1993). Yohimbine 
and tolazoline successfully antagonise xylazine-induced bradycardia and sedation. However, 
yohimbine has a quicker onset and shorter duration of action compared with tolazoline. Yohimbine 
is also associated with tremors, agitation and excitement, while tolazoline does not demonstrate 
these behavioural signs in xylazine treated horses. Tolazoline results in a normalisation of the heart 
rate to baseline readings but is associated with systemic hypertension in the presence of xylazine-
induced bradycardia (Kollias-Baker et al 1993).  
DEXMEDETOMIDINE 
 
Dexmedetomidine is considered to have greater selectivity for the alpha-2 receptor compared with 
its racemate (Aantaa et al 1993) and twice the potency of medetomidine (Savola & Virtanen, 1991; 
Bettschart-Wolfensberger et al 1999a,b; Kuusela et al 2000). While dexmedetomidine is associated 
with potent sedative and analgesic effects, levomedetomidine has been shown to potentiate the 
bradycardia as well as reduce the magnitude of sedative and analgesic effects from 
dexmedetomidine but only when levomedetomidine is administered at high doses (Kuusela et al 
2001). The analgesic effects of dexmedetomidine have not been studied in the horse. A study 
performed in dogs reports that the analgesia produced by intra-venous dexmedetomidine 
administration (20 lg/kg) is of similar magnitude but of longer duration (40 min) compared with the 
one obtained with an equipotent dose of medetomidine (Kuusela et al 2000). On the other hand, a 
study in cats (Slingsby & Taylor 2008) reported that only high doses of dexmedetomidine (40 
lg/kg) produced thermal antinociceptive effects, which peaked at 30 min and quickly returned to 
baseline. A short-lived period of analgesia was also reported in another study after a similar dose of 
dexmedetomidine was administered to cats (Slingsby et al 2010). Recently, a continuous infusion of 
dexmedetomidine was shown to decrease the minimum alveolar concentration of sevoflurane in 
ponies by 53% (Gozalo-Marcilla et al 2012).  
In a study performed in ponies, the cardiovascular effects of dexmedetomidine were considered to 
be somewhat similar to those caused by other a alpha-2 receptor agonists, but of very short 
duration. No bradycardia was observed, and stroke volume was reduced only for the first 5 min 
(Bettschart-Wolfensberger et al 2005). This same study also evaluated the pharmacokinetics of 
dexmedetomidine in ponies and demonstrated a rapid decrease in the drug’s plasma concentration, 
which may favour its use for short procedures as well as a continuous infusion for standing sedation 
or as an adjunct during general anaesthesia.  
The characteristics of dexmedetomidine indicate that the drug has important potential for use in 
equine anaesthesia; however, the knowledge of its pharmacokinetic and pharmacodynamic effects 
in the horse is limited.  
  
ATIPAMEZOLE 
 
ATZ is a potent, highly selective α2-adrenoceptor antagonist (Ramseyer et al 1998). There is a lack 
of pharmacokinetic and pharmacodynamics studies based on ATZ administered alone in horses. 
ATZ antagonism of detomidine-induced sedation (Ramseyer et al 1998) and bradycardia (Raekallio 
et al 1990) have been studied in horses. ATZ results in satisfactory but incomplete reversal of 
detomidine-induced sedation (Raekallio et al 1990; Ramseyer et al 1998). However, the level of 
ataxia is reduced significantly this allows the horse to ambulate properly (Ramseyer et al 1998). 
ATZ demonstrates a dose dependant increase in undesirable effects such as sweating, 
hyperexcitability in horses subjected to external stimuli and head shaking that tended to resolve 
within 10–15 min of injection in detomidine treated horses. Visual signs of arousal are apparent 
within 2min of IV administration (Ramseyer et al 1998). ATZ transiently antagonises detomidine-
induced bradycardia, decreases the frequency of atrioventricular blocks and normalises the arterial 
blood pressure (Raekallio et al 1990). ATZ effectively antagonises medetomidine constant rate 
infusion-induced sedation without causing untoward excitement. However, within 2 min of 
injection, the horse or pony should raise their head, become alert and may even demonstrate signs 
of shivering and intolerance to surgical drapes or physiological parameter (electrocardiogram leads, 
noninvasive blood pressure cuffs, etc) monitoring instrumentation (Bettschart-Wolfensberger et al 
1999). ATZ also antagonises medetomidine (Yamashita et al 1996) or xylazine- (Luna et al 1992) 
induced sedation after a single IV bolus with no apparent undesirable effects. 
A novel peripheral α2-adrenoceptor antagonist known as MK-467 (previously L-659’066) has been 
studied on detomidine sedated horses (Vainionpää et al 2013). MK-467 prevents detomidine-
induced bradycardia and gastrointestinal hypomotility without affecting the quality of sedation. In 
dogs, MK-467 has been investigated more comprehensively and demonstrates cardiovascular 
sparing effects without compromising on the level of sedation or general anaesthesia (Honkavaara 
et al 2011; Rolfe et al 2012; Salla et al 2014). Dexmedetomidine induced alterations in glucose, 
insulin, free fatty acids and lactate levels are attenuated by MK-467 (Restitutti et al 2012).  
  
AIM OF THE STUDY 
 
It is not uncommon for equine clinicians to deal with fractious horses in their everyday practice. A 
recent survey conducted by BEVA shows that equine veterinarians in the UK carry the highest risk 
of injury of any civilian occupation (BEVA 2014). 
Even though in the majority of the cases physical restrain of the patient is enough to allow a safe 
execution of the diagnostic analgesia, sometimes this is not enough. In those circumstances 
performing a nerve block can become a very dangerous procedure for both the patient and the 
operators/owner. This is exacerbated when the horse is assessed in an unfamiliar environment such 
as in a veterinary hospital. The lameness investigation can produce a great amount of stress in the 
patient that could lead to uncontrolled reactions with the potential for personnel to get seriously 
injured. So far the use of chemical restraint has always been discouraged because of the undesired 
effects produced by sedative drugs such as ataxia and sedation. 
The aim of the present study was to analyse the efficacy and applicability of a sedation protocol 
with DEX and antagonism with ATZ for use in clinical settings when performing diagnostic 
analgesia in horses. 
 
  
MATERIALS AND METHODS 
 
In order to perform this study six healthy horses were recruited (3 males and 3 females) of different 
breeds (one Arab, two Sella Italiano and three sports horses). The average age was 11.5 ± 6.68 
(average ± standard deviation) (range 5-20 year old) and the body weight 455± 67.9 kg (range 366-
561 kg). 
 
During the period of the study the horses were stabled in boxes with shavings and fed hay with a 
minimal grains intake and water ad lib. 
 
Before performing the study each horse was weighted, and clinically examined with particular 
attention to heart rate (HR), respiratory rate (RR) (lungs sounds were listened too), mucous 
membranes colour (MM), capillary refill time (CRT), hydration status and rectal temperature (T°). 
 
The main reference for the assessment of the degree of sedation was the height of the lower lip from 
the ground. During the days preceding the study the height of the lower lip from the ground was 
measured under normal conditions with the horse conscious. The values obtained were divided by 
10 and 3 reference values were marked on the wall of the stable as a reference. The reference height 
of the head was marked as well as two other values indicating a 10% increase and reduction of the 
resting value. These two parameters were used to ascertain that the value obtained was 
representative of the single horse. 
The horse was further monitored to make sure that the height of the lip was constantly staying 
between the marked ranges. Every horse has then been moved in the hallway were a graduated scale 
corresponding to the one drawn in the stable had previously been drawn on the wall. 
 
The horses were then sedated with DEX IV. The administered dose was adjusted depending on the 
degree of awareness and behaviour at the time of sedation (range 2.5 to 5µg/kg).  
 
Between 5 and 10 minutes after the sedation was administered, the diagnostic block was performed. 
This consisted of high plantar nerve block (1 horse) bilateral lateral plantar nerve block in 2 horses 
and dorsal spinous processes anaesthesia in the other 3 cases. 
 
The local anaesthetic used for all the nerve blocks mepivacaine 2% (Intra epicaine®). 
For the high plantar nerve block the leg was left weight bearing and two 21G 4cm needles were 
used (one for each side). The volume of local anaesthetic used was 10 mls in total. 
For the lateral plantar nerve block, the limb was positioned on the operator’s leg and a using a 23 G 
x2.5 cm needle used. The volume of local anaesthetic used was 1 ml. 
For the block of the interspinous space, a 19 G x 9 cm needle was used. The volume of local 
anaesthetic used was 5 mls for each interspinous space involved.  
The same operator performed the diagnostic analgesia in all the cases.  
 
After 20 minutes the antagonist was administered with an equal volume (ATZ 50 µg/kg IV) to the 
one of DEX administered. 
The following clinical parameters were considered: HR, RR, MM, CRT and quality of the 
peripheral pulse. Every adverse effect (i.e. arrhythmia) presenting after the administration of DEX 
was recorded. Degree of stability, ataxia, response to tactile, visual and acoustic stimuli was 
recorded and used to assess the degree of sedation together with the height of the lip from the 
ground. The response to the touch of the ear was also assessed. 
The assessments were performed at 3, 5, 10 and 15 min after the administration of DEX and 3, 5, 
10, 15 min after the administration of atipamezole. 
The HR was assessed with a stethoscope whereas the RR was assessed counting the number of 
excursions of the thorax.  
The quality of the pulse was assessed (always by the same operator) at the level of the facial artery.  
 
The degree of sedation was assessed using the VAS previously described by Ringer et al 2013. The 
visual scale was chosen to assess the degree of sedation with a single value that was always given 
by the same operator. Whereas previously trained operators recorded the NRS scale values. 
 
An umbrella was used in order to assess the response to visual stimuli. This was suddenly opened in 
front of the animal. The acoustic response was assessed as response to the operator clapping their 
hands. Response to tactile stimuli was detected by applying increasing pressure to the heel bulb 
region with a blunt instrument (before the blocks were performed).  
 
Twenty minutes after ATZ administration and after all the previous parameters were collected, 
lameness investigation was continued. Any adverse reaction or relevant abnormality was recorded.  
Lameness investigation was performed by the same operator in all cases. 
 
A template of the assessment sheets is reported in the following pages. 
 
SEDATION sheet                                                         HORSE N. 
 
Administered drug:                                                                          dose 
Physiologic paramenters 
Time 3min 5min 10min 15min 20min 
HR      
RR      
Mucous      
Quality of 
pulse 
     
Detectable 
arrhythmias  
     
Other notes      
 
 
Sedation score 
Time 3min  5min 10min 15min 20min 
NRS VAS NRS VAS NRS VAS NRS VAS NRS VAS 
Standing 
ataxia 
          
Ataxia on 
movement 
          
Reaction 
to touch 
          
Touch of 
the ear  
          
Reaction 
to visible 
stimulae 
          
Reaction 
to audible 
stimulae 
          
 
 
 
Height 
head from 
the floor 
     
  
 
Fig. 1 – Positioning of the scale in the stable, in 
order to assess the basal value. 
 
Fig. 2 – Positioning of the animal next to the 
sedation scale before administering the sedation. 
 
  
 
Fig. 3 – Picture showing the skin sensitivity 
being tested. 
 
Fig. 4 – Picture showing the height of the lip 
from the floor after the sedation. 
  
STATISTIC ANALYSIS 
 
The recorded values were analysed with the t-test for paired samples (clinical parameters and height 
of the head) and non-parametric test of Wilcoxon was used for subjective parameters. Values were 
considered significant if p was less then 0.05 and highly significant if p less than 0.005. 
 
  
 RESULTS 
 
CLINICAL PARAMETERS 
 
In the present study HR and RR were subjected to statistic assessment, whereas MM, CRT, quality 
of the pulse and presence of arrhythmia were subjected to clinical evaluation. 
 
The results for the recorded parameters are reported in the following tables. 
 
HEART RATE 
 
Tab. Heart Rate               
Horse 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 32 32 32 32 32 32 32 36 
2 20 20 24 24 28 28 26 26 
3 28 32 28 28 28 32 28 32 
4 28 24 24 24 32 28 24 24 
5 24 24 28 32 32 28 28 28 
6 16 28 28 20 20 20 24 24 
 
Statistic for paired samples 
  Media N Standard deviation Average SD error 
Couple N 1 DEX3min 24,667 6 5,8878 2,4037 
ATZ3min 28,667 6 4,6762 1,9090 
Couple N 2 DEX5min 26,667 6 4,8442 1,9777 
ATZ5min 28,000 6 4,3818 1,7889 
Couple N 3 DEX10min 27,333 6 3,0111 1,2293 
ATZ10min 27,000 6 3,0332 1,2383 
Couple N 4 DEX15min 26,667 6 4,8442 1,9777 
ATZ15min 28,333 6 4,8028 1,9607 
 
  
 
 
 
Test for paired samples 
 
  
Difference between couples 
t df Sig. (2-code) Average SD 
Average  
SD 
error 
Confidence interval 
for 95% difference 
Inf Sup 
Couple 1 DEX3min - ATZ3min -4,0000 3,5777 1,4606 -7,7546 -,2454 -2,739 5 ,041 
Couple 2 DEX5min - ATZ5min -1,3333 5,4650 2,2311 -7,0685 4,4019 -,598 5 ,576 
Couple 3 DEX10min - ATZ10min ,3333 1,9664 ,8028 -1,7303 2,3969 ,415 5 ,695 
Couple 4 DEX15min - ATZ15min -1,6667 3,2042 1,3081 -5,0292 1,6959 -1,274 5 ,259 
 
It is possible to appreciate a statically significant difference between the group DEX and ATZ at 3 
min. Higher values are recorded for ATZ at 3 min. 
 
RESPIRATORY RATE 
 
Table RR               
Horse 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 10 12 12 12 16 16 16 16 
2 10 12 10 12 16 16 12 12 
3 12 16 10 12 12 16 20 16 
4 16 16 16 16 16 20 20 16 
5 12 12 20 12 12 12 12 12 
6 12 20 20 20 24 24 20 20 
 
 
 
Statistic for paired samples 
  Average N SD Average SD 
Couple 1 DEX3min 12,000 6 2,1909 ,8944 
ATZ3min 16,000 6 4,3818 1,7889 
Couple  2 DEX5min 14,667 6 3,2660 1,3333 
ATZ5min 
17,333 6 4,1312 1,6865 
Couple  3 DEX10min 14,667 6 4,6762 1,9090 
ATZ10min 16,667 6 3,9328 1,6055 
Couple  4 DEX15min 14,000 6 3,3466 1,3663 
ATZ15min 15,333 6 3,0111 1,2293 
  
It is possible to appreciate a statically significant difference between the group DEX and ATZ at 5 
min. Higher values are recorded for ATZ at 5 min. 
 
SUBJECTIVE PARAMETERS OF THE SEDATION SCALE 
 
The subjective parameters were assessed with two different scales of sedation, NRS and VAS. The 
results for each parameter are reported below. 
 
Difficulty in maintaining a still posture 
 
 
 
 
 
 
  
 
Test for paired samples  
 
  
Difference between couples 
t df Sig. (2-code) Average SD Average SD error 
Confidence interval 
for 95% difference 
Inf Sup 
Couple 1 DEX3min - ATZ3min -4,0000 4,8990 2,0000 -9,1412 1,1412 -2,000 5 ,102 
Couple  2 DEX5min - ATZ5min -2,6667 2,0656 ,8433 -4,8344 -,4990 -3,162 5 ,025 
Couple  3 DEX10min - ATZ10min -2,0000 5,9330 2,4221 -8,2263 4,2263 -,826 5 ,447 
Couple  4 DEX15min - ATZ15min -1,3333 2,0656 ,8433 -3,5010 ,8344 -1,581 5 ,175 
Tab. For the ability of 
maintaining a still posture             
Horse 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 2 1 1 1 0 0 0 0 
2 1 1 1 1 0 0 0 0 
3 1 1 1 1 0 0 0 0 
4 1 1 1 1 0 0 0 0 
5 1 1 1 1 0 0 0 0 
6 1 1 1 1 0 0 0 0 
Report 
 
DEX3min DEX5min DEX10min DEX15min ATZ3min ATZ5min ATZ10min ATZ15min 
Average 1,167 1,000 1,000 1,000 0,000 0,000 0,000 0,000 
SD ,4082 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 
E. S. from average ,1667 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 0,0000 
Testa,c 
  
ATZ3min - 
DEX3min 
ATZ5min - 
DEX5min 
ATZ10min - 
DEX10min 
ATZ15min - 
DEX15min 
Z -2,333b -2,449b -2,449b -2,449b 
Sig. Asint. a 2 code ,020 ,014 ,014 ,014 
Monte Carlo a 2 
code Signif 
Sig. ,030 ,030 ,030 ,030 
Conf interval 
99% 
Lower 
Limit ,026 ,025 ,025 ,025 
Upper 
limit ,035 ,034 ,034 ,034 
Monte Carlo a 1 
coda signif  
Sig. ,016 ,017 ,017 ,017 
Conf interval 
99% 
Lower 
Limit ,013 ,013 ,013 ,013 
Upper 
limit ,019 ,020 ,020 ,020 
a. Wilcoxon test 
b. Based on positive ranks. 
c. Based on 10000 tables of samples 2000000. 
 
This parameter was significant in all groups showing an increased instability amongst the groups 
DEX compared to the groups ATZ. In the ATZ group no signs of instability were noticed. 
 
ATAXIA 
 
Tab. For ataxia             
Horse 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 2 2 2 2 0 0 0 0 
2 2 2 2 2 1 1 1 1 
3 3 3 2 2 1 1 0 0 
4 1 1 1 1 0 0 0 0 
5 2 2 2 2 0 0 0 0 
6 2 3 2 2 1 1 1 0 
 
 
 
 
 
 
 
  
Report 
  DEX3min DEX5min DEX10min DEX15min ATZ3min ATZ5min ATZ10min ATZ15min 
Average 2,000 2,167 1,833 1,833 ,500 ,500 ,333 ,167 
SD ,6325 ,7528 ,4082 ,4082 ,5477 ,5477 ,5164 ,4082 
E. S. from average ,2582 ,3073 ,1667 ,1667 ,2236 ,2236 ,2108 ,1667 
 
 
Testa,c 
  
ATZ3min - 
DEX3min 
ATZ5min - 
DEX5min 
ATZ10min - 
DEX10min 
ATZ15min - 
DEX15min 
Z -2,251b -2,271b -2,251b -2,271b 
Sig. Asint.  ,024 ,023 ,024 ,023 
Monte Carlo double 
Signif 
Sig. ,028 ,030 ,028 ,030 
Conf interval  
99% 
Lower 
Limit ,024 ,026 ,024 ,026 
Upper 
limit ,032 ,034 ,032 ,034 
Monte Carlo single 
code Signif 
Sig. ,014 ,014 ,014 ,014 
Conf interval 
99% 
Lower 
Limit ,011 ,011 ,011 ,011 
Upper 
limit ,017 ,016 ,017 ,016 
a. Wilcoxon test 
b. Based on positive ranks 
c. Based on 10000 tables of samples 624387341. 
 
In all the groups the degree of Ataxia was significantly reduced in the group ATZ at 3 minutes. 
 
RESPONSE TO TOUCH 
 
Tab. Response to the touch             
Horse 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 3 3 3 3 1 1 1 1 
2 3 3 3 3 1 1 1 1 
3 3 3 3 3 3 1 1 1 
4 3 3 1 1 3 0 1 0 
5 3 3 3 3 2 1 1 1 
6 3 3 3 3 3 2 3 1 
 
 
 
  
Report 
  DEX3min DEX5min DEX10min DEX15min ATZ3min ATZ5min ATZ10min ATZ15min 
Average 3,000 3,000 2,667 2,667 2,167 1,000 1,333 ,833 
SD 0,0000 0,0000 ,8165 ,8165 ,9832 ,6325 ,8165 ,4082 
E. S. from average 0,0000 0,0000 ,3333 ,3333 ,4014 ,2582 ,3333 ,1667 
Testa,c 
  
ATZ3min - 
DEX3min 
ATZ5min - 
DEX5min 
ATZ10min - 
DEX10min 
ATZ15min - 
DEX15min 
Z -1,633b -2,264b -2,000b -2,333b 
Sig. Asint. double ,102 ,024 ,046 ,020 
Monte Carlo double 
Signif 
Sig. ,248 ,033 ,124 ,032 
Conf 
interval  
99% 
Lower 
Limit ,237 ,028 ,116 ,027 
Upper 
limit ,259 ,037 ,133 ,036 
Monte Carlo single 
Signif 
Sig. ,123 ,015 ,061 ,016 
Conf 
interval  
99% 
Lower 
Limit ,114 ,012 ,055 ,013 
Upper 
limit ,131 ,018 ,067 ,019 
a. Wilcoxon test 
b. Based on positive ranks 
c. Based on 10000 tables of samples 957002199. 
The difference noticed for this parameter was shown to be statistically significant between the two 
groups at 5 min. Horses in the group DEX were less responsive to stimuli. 
 
RESPONSE TO VISUAL STIMULI 
 
Tab. Response to visual stimuli           
Horsee 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 2 3 3 3 0 0 0 0 
2 1 1 2 2 1 1 0 0 
3 1 1 2 2 0 0 0 0 
4 2 2 2 2 1 1 1 0 
5 3 2 2 1 0 0 0 0 
6 2 1 1 1 0 0 0 0 
 
Report 
  DEX3min DEX5min DEX10min DEX15min ATZ3min ATZ5min ATZ10min ATZ15min 
Average 1,833 1,667 2,000 1,833 ,333 ,333 ,167 0,000 
SD ,7528 ,8165 ,6325 ,7528 ,5164 ,5164 ,4082 0,0000 
E. S. from average ,3073 ,3333 ,2582 ,3073 ,2108 ,2108 ,1667 0,0000 
 
  
  
A statistically significant difference was present between the groups DEX and ATZ at 10 and 15 
min. The values are reduced in the groups ATZ suggesting a decreased response to visual stimuli at 
10 and 15 min. 
 
RESPONSE TO ACOUSTIC STIMULI 
 
Tab. Response to acoustic stimuli           
Horse 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 1 2 2 2 2 0 0 0 
2 1 1 1 1 1 1 1 1 
3 1 1 2 2 1 1 0 0 
4 3 2 1 1 1 0 0 0 
5 3 3 3 3 0 0 0 0 
6 2 3 1 1 0 0 0 0 
 
Report 
  DEX3min DEX5min DEX10min DEX15min ATZ3min ATZ5min ATZ10min ATZ15min 
Average 1,833 2,000 1,667 1,667 ,833 ,333 ,167 ,167 
SD ,9832 ,8944 ,8165 ,8165 ,7528 ,5164 ,4082 ,4082 
E. S. from average ,4014 ,3651 ,3333 ,3333 ,3073 ,2108 ,1667 ,1667 
 
  
Testa,c 
  
ATZ3min - 
DEX3min 
ATZ5min - 
DEX5min 
ATZ10min - 
DEX10min 
ATZ15min - 
DEX15min 
Z -2,041b -2,060b -2,232b -2,232b 
Sig. Asint. double ,041 ,039 ,026 ,026 
Monte Carlo 
double Signif 
Sig. ,063 ,066 ,034 ,034 
Conf interval  
99% 
Lower 
Limit ,057 ,060 ,029 ,029 
Upper 
limit ,070 ,073 ,039 ,039 
Monte Carlo single 
Signif   
Sig. ,034 ,035 ,018 ,018 
Conf interval 
99% 
Lower 
Limit ,029 ,030 ,015 ,015 
Upper 
limit ,039 ,040 ,022 ,022 
a. Wilcoxon test 
b. Based on positive ranks 
c. Based on 10000 tables of samples 92208573. 
Testa,c 
  
ATZ3min - 
DEX3min 
ATZ5min - 
DEX5min 
ATZ10min - 
DEX10min 
ATZ15min - 
DEX15min 
Z -1,473b -1,857b -2,041b -2,041b 
Sig. Asint. double ,141 ,063 ,041 ,041 
Monte Carlo double 
Signif 
Sig. ,253 ,128 ,064 ,064 
Conf 
interval  
 99% 
Lower 
Limit ,241 ,119 ,058 ,058 
Upper 
limit ,264 ,136 ,071 ,071 
Monte Carlo single 
Signif 
Sig. ,126 ,065 ,031 ,031 
Conf 
interval  
99% 
Lower 
Limit ,118 ,058 ,027 ,027 
Upper 
limit ,135 ,071 ,036 ,036 
a. Wilcoxon test 
b. Based on positive ranks 
c. Based on 10000 tables of samples 1993510611. 
No statistically significant difference was identified. 
 
HEIGHT OF THE HEAD 
Tab. Eight of the 
head               
 Horse 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 43 31 28 36 94 103 103 103 
2 20 20 25 23 95 105 115 115 
3 50 40 45 40 63 80 100 100 
4 23 20 33 33 28 84 75 74 
5 28 20 32 30 80 100 80 80 
6 50 40 30 30 65 75 65 60 
 
Test for paired samples 
  Average N SD 
Average  
standard error 
Couple 1 DEX3min 35,667 6 13,6333 5,5658 
ATZ3min 70,833 6 25,0393 10,2223 
Couple 2 DEX5min 28,500 6 9,8742 4,0311 
ATZ5min 91,167 6 13,0141 5,3130 
Couple 3 DEX10min 32,167 6 6,9113 2,8215 
ATZ10min 89,667 6 19,2007 7,8387 
Couple 4 DEX15min 32,000 6 5,8310 2,3805 
ATZ15min 88,667 6 20,6849 8,4446 
  
   Height of the head (cm) 
Average pre-sedation 115,66 
50% Average pre-
sedation 57,83 
Average DEX 3min 35,667* 
Average DEX 5 min 28,5* 
Average DEX 10min 32,167* 
Average DEX 15min 32* 
Average ATZ 3min 70,833 
Average ATZ 5min 91,167 
Average ATZ 10min  89,667 
Average ATZ 15min 88,667 
 
*= values lower than the 50% of the average of the height of the head measured before sedation. 
Test for paired samples 
  
Difference in couples 
t df Sig. (2-code) Average SD 
Average  
standard error 
Confidence interval 
for 95% difference 
Lower Upper 
Couple 1 DEX3min - ATZ3min -35,1667 28,0315 11,4438 -64,5840 -5,7494 -3,073 5 ,028 
Couple 2 DEX5min - ATZ5min -62,6667 20,8199 8,4997 -84,5158 -40,8176 -7,373 5 ,001 
Couple 3 DEX10min - ATZ10min -57,5000 21,0024 8,5742 -79,5406 -35,4594 -6,706 5 ,001 
Couple 4 DEX15min - ATZ15min -56,6667 21,7593 8,8832 -79,5016 -33,8317 -6,379 5 ,001 
 
For this value it was possible to appreciate a statistically significant difference starting from 3 min 
suggesting a rapid response to the administration of ATZ. 
 
VAS 
 
VAS scale 
VAS              
Horse 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 8 7 7 7 4 4 3 2 
2 8 8 8 8 3 2 2 2 
3 7 7 7 7 3 2 1 1 
4 8 7 7 7 6 2 1 1 
5 9 9 8 8 3 1 1 1 
6 8 9 9 8 6 4 3 2 
 
 
 
 
Report 
  DEX3min DEX5min DEX10min DEX15min ATZ3min ATZ5min ATZ10min ATZ15min 
Average 8,000 7,833 7,667 7,500 4,167 2,500 1,833 1,500 
SD ,6325 ,9832 ,8165 ,5477 1,4720 1,2247 ,9832 ,5477 
E. S. from average ,2582 ,4014 ,3333 ,2236 ,6009 ,5000 ,4014 ,2236 
 
Testa,c 
  
ATZ3min - 
DEX3min 
ATZ5min - 
DEX5min 
ATZ10min - 
DEX10min 
ATZ15min - 
DEX15min 
Z -2,214b -2,226b -2,264b -2,264b 
Sig. Asint. double ,027 ,026 ,024 ,024 
Monte Carlo 
double Signif 
Sig. ,031 ,032 ,031 ,031 
Conf interval 
99%  
 
Lower 
Limit ,027 ,028 ,026 ,026 
Upper 
limit ,036 ,037 ,035 ,035 
Monte Carlo single 
Signif 
Sig. ,016 ,016 ,015 ,015 
Conf interval 
99% 
Lower 
Limit ,012 ,013 ,012 ,012 
Upper 
limit ,019 ,020 ,018 ,018 
a. Wilcoxon test 
b. Based on positive ranks 
c. Based on 10000 tables of samples 79654295. 
For this parameter the results were increased in the group DEX compared to ATZ suggesting a 
deeper level of sedation. This was also statistically significant. 
 
SUM OF SUBJECTIVE PARAMETERS 
Table of the sum 
 
        
Horse 
DEX 
3min 
DEX 
5min 
DEX 
10min 
DEX 
15min 
ATZ 
3min 
ATZ 
5min 
ATZ 
10min 
ATZ 
15min 
1 10 12 11 11 3 1 1 1 
2 8 8 9 9 4 3 3 2 
3 9 9 10 10 5 3 1 1 
4 10 9 6 6 5 1 2 0 
5 12 11 11 10 2 1 1 1 
6 10 10 8 8 4 3 4 1 
 
This parameter was statistically significant in all the groups with higher values for the group DEX. 
These results indicate an increased degree of sedation for the group DEX. 
  
Report 
  DEX3min DEX5min DEX10min DEX15min ATZ3min ATZ5min ATZ10min ATZ15min 
Average 9,833 9,833 9,167 9,000 3,833 2,000 2,000 1,000 
SD 1,3292 1,4720 1,9408 1,7889 1,1690 1,0954 1,2649 ,6325 
E. S. from average ,5426 ,6009 ,7923 ,7303 ,4773 ,4472 ,5164 ,2582 
 
Testa,c 
  
ATZ3min - 
DEX3min 
ATZ5min - 
DEX5min 
ATZ10min - 
DEX10min 
ATZ15min - 
DEX15min 
Z -2,207b -2,201b -2,214b -2,214b 
Sig. Asint. ,027 ,028 ,027 ,027 
Monte Carlo 
double Signif 
Sig. ,031 ,033 ,036 ,032 
Conf Interval 
99% 
Lower 
Limit ,026 ,029 ,031 ,027 
Upper 
limit ,035 ,038 ,040 ,036 
Monte Carlo single 
Signif 
Sig. ,016 ,018 ,018 ,016 
Conf Interval 
99% 
Lower 
Limit ,013 ,014 ,015 ,013 
Upper 
limit ,019 ,021 ,022 ,020 
a. Wilcoxon test 
b. Based on positive ranks 
c. Based on 10000 tables of samples 475497203. 
 
 
All the horses were able to complete the lameness investigation without requiring further ATZ 
administration. 
  
 DISCUSSION 
 
Although a thorough clinical examination during a lameness investigation is mandatory in every 
lameness case, there is no question that clinical examination can be misleading (Pilsworth & Dyson 
2015). The use of diagnostic analgesia to accurately localise the source of pain is therefore essential 
(Pilsworth & Dyson 2015). Due to the costs involved in using modern imaging techniques the 
decision for further diagnostic tests should be based upon the correct localisation of the area with 
diagnostic analgesia.  
 
Different methods have previously been used in order to restrain fractious horses in order to 
perform diagnostic analgesia. These include nose twitch, ear or skin twitch. However, sometimes 
the reaction of the patient to these forms of restraint can be unpredictable with increased risk of 
injury for the operators involved in the procedure.  
 
Tranquilization is sometimes necessary when clinically assessing lameness in exuberant, nervous or 
excited horses, in order to avoid masking of clinical signs (López-Sanromán et al 2015). However, 
a consensus on whether use of sedatives should be allowed during lameness investigation has not 
been achieved yet. It has previously been suggested that sedation of fractious and/or excited horses 
may lead to a better identification of the lameness (Schumacher et al 2013). Furthermore even in 
cases where sedation was deemed useful and necessary there was not agreement on which drug 
should be used (Schumacher et al 2013, Ross 2012, Kollias-Baker et al 1993). 
 
Sedation with detomidine did not change the degree of lameness, but it did alter the general 
locomotion pattern suggesting that its use could be more beneficial in those cases where a more 
prolonged duration of effects is required (Buchner et al 1999, Ross 2012). The use of xylazine can 
be advocated in those instances where a shorter duration of action is required. After xylazine 
administration the majority of accelerometric parameters showed significant differences only until 
45 min after injection (López-Sanromán et al., 2012). However mild ataxia should be considered as 
a possible side effect (Buchner et al 1999, Schumacher et al 2013). 
 
When the intravenous administration of romifidine, detomidine and xylazine were compared it was 
found that romifidine administration caused the least effect on accelerometric variables even though 
a statistic significance was not established. However the duration of the effect was significantly 
longer (López-Sanromán et al 2013). In the study the horses were assessed at walk before and 5, 15, 
30, 45, 60, 75, 90, 105, and 120 minutes after each treatment. No difference in the stride length was 
detected among treatments and between treatments and control group. 
 
The use of a different route of administration for alpha2-agonists has also been considered on the 
basis that different absorption could have modified the effect of the drug on the musculoskeletal 
system. When the effect of sublingual administration of detomidine on kinematic parameters was 
assesses it was shown that significant differences with baseline values were observed 180 minutes 
after administration, thus indicating a prolonged effect of the drug when administered sublingually 
(López-Sanromán et al 2014). In the former study the prolonged ataxia was attributed to the 
alteration of the regularity values of the stride that subsequently led to a decrease in stability. It is 
logic to think that the results obtained in this study at walk would be even more pronounced when 
the horse is trotted on straight line and particularly on the lunge for a thorough lameness 
investigation. 
In the last decade the use of more recent and specific alpha-2 agonists has greatly increased. In the 
United States of America the use of DEX has largely replaced the use of less specific drugs (i.e. 
detomidine) (Rezende et al 2014). A pharmacokinetic study showed that after intravenous 
administration of DEX at the dose of 5µg/kg IV the maximum degree of sedation was noticed 
between 4 and 10 minutes. Lowering of the head and lack of interest in the surroundings were in 
fact to be 70% less compared to baseline (Rezende et al 2014). Head height gradually returned to 
normal and was only 20% lower than baseline at 60 min. The ability to ambulate was also assessed. 
A significant reduction was assessed during the first 60 minutes. Response to different stimuli was 
also significantly reduced until 30 minutes after administration. The authors concluded that 
Dexmedetomidine produced intense sedation and severe ataxia as indicated by the decrease in head 
height and elevation of gait scores. While significant sedation was observed up to 60 min post-drug 
administration, it was most intense during the initial 20–30 min (albeit still statistically significant, 
at 45 and 60 min the head height was only 30% and 20% lower than baseline, respectively) 
(Rezende et al 2014). Even though the elimination half life of DEX was 8.03 +/- 0.84 min, it was 
considered that antagonism of the molecule was appropriate to entirely antagonise the sedation and 
also to “remove” the analgesic effect provided by DEX. 
 
In veterinary medicine the use of DEX had drastically increased due to its increased specificity for 
alpha-2 receptor and therefore reduced side effects. Furthermore the availability of a specific 
antagonist (ATZ) for DEX made its use in the everyday practice even safer (Corletto 2010).  
 In order to assess the degree of sedation and therefore the effect of the ATZ administration NRS 
and VAS scores were used. The variables assessed were the same previously used in other studies 
(Ringer et al 2013). 
 
The horses included in this study were admitted to the hospital 2 days before the study was 
performed in order to allow enough time for acclimatisation. This enabled repeated measurements 
in order to correctly identify a baseline value for the Head Height Above the Ground (HHAG). In 
fact, to date this is the best objective measurement of the degree of sedation (Bryant et al, 1991; 
Clarke et al, 1991; England et al, 1992; Hamm et al, 1995; Freeman & England, 1999; Figueiredo 
et al, 2005). 
In this study the HHAG showed a statistically significant value at all the points in time indicating a 
rapid sedative effect of DEX but also a rapid antagonism effect of ATZ.  
 
A statistically significant difference was found for the HR 3 min after sedation and 3 min after 
antagonism. The ATZ was able to fully reverse the bradycardia induced by the administration of 
DEX. A statistically significant difference was also found in both groups at T5 suggesting a 
complete antagonism of the respiratory effects too. 
 
The ability of the horse to stand in a still position was statistically significant in both groups at any 
point in time indicating a good degree of both sedation and antagonism. After sedation the horses 
were experiencing a certain degree of sway that completely disappeared after administration of 
ATZ. The degree of ataxia was markedly increased in horses after the administration of DEX. This 
finding is supported by previous studies suggesting a marked degree of ataxia after DEX 
administration (Rezende et al 2014). The degree of ataxia was significantly reduced already 3 min 
after ATZ administration. In this study the same operator subjectively assessed the degree of ataxia. 
However it is our intention to perform further studies with a more objective measurement of the 
degree of ataxia using an accelerometer. 
 
The skin sensitivity of horses after sedation was significantly reduced in 5 of the horses included in 
the study. This is a very important finding because it means that needle positioning will be less 
likely to cause reaction and therefore reduce the risk of needle breakage. It was deemed essential to 
assess this parameter before the block was performed in order to evaluate the response of the horse 
with respect to personnel safety.  
 In the present study it was possible to perform diagnostic analgesia in all the horses. In two cases a 
bilateral lateral plantar nerve block was performed. Even though the degree of ataxia was increased 
after DEX administration it was possible to lift the leg and perform the nerve block. The only 
inconvenient was the reduced response to lift the leg. However with a second operator performing 
this procedure the block could easily be performed. 
In the other three cases a dorsal spinous ligament block and the high plantar nerve block were 
performed without any reaction. 
 
It is important to take into account the type of anaesthetic block performed because in some cases 
20 min could be too long to guarantee an acceptable specificity of the block (i.e coffin joint and 
navicular bursa) 
 
The response to visual stimuli was significantly different at 10 and 15 minutes in each group. There 
was not statically significant difference for the acoustic stimuli. This was an unexpected finding 
which did not fit the clinical presentation. Even though horses after sedation still presented a 
response to acoustic stimuli it was markedly reduced compared to horses after administration of 
antagonist. The noise produced by hand clapping has been shown to be 130 dB (A). Considering 
that threshold for noise perception in horses is 7dB in a range of frequencies between 33.5 to 55 
kHz (Heffner & Heffner 1983) we could speculate that the response in sedated horses with just a 
head could be considered mild. So it would be appropriate to perform further studies with a known 
source of noise in order to allow more objective measurements. 
 
When the overall sedation scores are assessed it is possible to appreciate a statistically significant 
difference between the group DEX and ATZ at any point in time. This can also be clearly 
appreciated from a clinical point of view. 
 
The protocol presented in this study fulfilled the objectives presented in the aim of the study. 
However, the clinical applications of this protocol still present some limitations such as costs. One 
vial of DEX 0.5 mg/ml (10mls) costs in average 67 €. Considering the doses used in our study for 
an average 500 Kg horse 1 ml every 100Kg is needed costing in total 33.5 €. The cost of the 
antagonist for the same horse is 27.5€ bringing the total cost to 61€.  
Furthermore the use of a single molecule would increase the risk of a sudden arousal. In order to 
avoid that it is common practice to use a multimodal approach with different drugs. The reason why 
this protocol was designed does not allow use of different drugs that could potentially not be 
reversed. 
The “repeatability” of the protocol should also be considered. When the protocol has been 
administered to a patient it is not possible to repeat it within a short period of time. This gives to the 
clinician “one shot” to perform the diagnostic analgesia. 
  
CONCLUSIONS 
 
The protocol proposed in this preliminary study was able to provide a good level of sedation and a 
fast antagonism. It is important to highlight that ataxia was completely antagonised by the 
administration of ATZ in 4 out of 6 cases. However in the other two cases the recovery was 
considered satisfactory in order to perform an orthopaedic exam. We would expect that with a 
greater number of cases and an objective measurement (accelerometer) will allow us to document 
the degree of ataxia objectively. 
 
The protocol was also safe allowing the clinician to perform the procedure without time pressure 
and without any injuries occurring. This allows the equine surgeon to perform diagnostic analgesia 
on fractious horses in a yard setting where transport is not possible. 
 
The reduced number of the sample and the static, suggest that the number should be increased at 
least 4 folds in order to validate the method for the clinical use. 
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